In this study, we investigated how gene variants of the activating NK cell receptors including NKG2D, DNAM-1 and NKp30 impact on clinical outcome and receptor expression in a cohort of AML patients receiving IL-2-based immunotherapy. This evidence concerns the gene CD226 and acute myeloid leukemia.